Skip to main content

Table 2 Changes in baseline characteristics seen after treatment with carvedilol.

From: Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study

 

Before carvedilol

(N = 9)

After carvedilol

(N = 9)

% Change after treatment

P-value

Body weight (kg)

89.72 ± 7.10

90.32 ± 7.39

0.6%

0.43

BMI (Kg/m²)

29.26 ± 1.76

29.48 ± 1.87

o.8%

0.39

Systolic BP (mm Hg)

142.4 ± 5.09

136.9 ± 5.80

-3.7%

0.38

Diastolic BP (mm Hg)

71.4 ± 2.59

61.3 ± 3.13³

-14.1%

0.003

Heart rate (beats/min)

67.1 ± 2.16

60.7 ± 1.74³

-9.5%

0.02

Fasting glucose (mmol/L)

8.61 ± 0.78

9.66 ± 1.31

12.2%

0.20

Fasting insulin (μU/L)

10.20 ± 3.20

13.75 ± 8.42

34.8%

0.68

Hb A1c (%)

7.6 ± 0.59

7.66 ± 0.76

0.8%

0.95

Total Cholesterol (mmol/L)

4.12 ± 0.28

4.48 ± 0.35

8.7%

0.06

LDL (mmol/L)

2.29 ± 0.31

2.5 ± 0.30

9.2%

0.10

HDL (mmol/L)

1.19 ± 0.06

1.24 ± 0.09

4.2%

0.37

TG (mmol/L)

1.41 ± 0.27

1.57 ± 0.28

11.3%

0.38

CRP (mmol/L)

3.00 ± 0.44

2.89 ± 0.26

-3.7%

0.68

  1. T2DM: Patients with Type 2 Diabetes; M/F: Male/Female; ACE inhibitors: Angiotensin Converting Enzyme inhibitors; AT2B: Angiotensin 2 Blockers; BMI: Body Mass Index, BP: Blood Pressure; Hb A1c: Glycosylated Hemoglobin A1c; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; TG: TriGlyceride; CRP: C-Reactive Protein.